Medical device maker AtriCure beats Q3 revenue estimates

AtriCure

29/10/2025 20:12

Overview

AtriCure Q3 2025 revenue grows 15.8% yr/yr, beating analyst expectations

Adjusted EPS for Q3 2025 beats consensus, reflecting improved financial performance

Company raises full year 2025 revenue and adjusted EBITDA guidance

Outlook

AtriCure expects full-year 2025 revenue forecast to $532 mln-$534 mln

Company expects full-year 2025 Adjusted EBITDA of $55 mln-$57 mln

AtriCure anticipates full-year 2025 adjusted loss per share of $0.23-$0.26

Result Drivers

PRODUCT ADOPTION - Strong adoption of AtriClip, EnCompass, and cryoSPHERE devices drove revenue growth

GEOGRAPHIC EXPANSION - International revenue increased by 22%, driven by broad growth across franchises and regions

INNOVATION INVESTMENTS - Investments in product innovation and clinical science are building future growth catalysts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$134.30 mln
$131.25 mln (9 Analysts)
Q3 Adjusted EPS
-$0.01
-$0.11 (9 Analysts)
Q3 Adjusted EBITDA
Beat
$17.80 mln
$11.65 mln (7 Analysts)
Q3 Gross Margin
75.50%
Q3 Gross Profit
$101.30 mln
Q3 Operating Income
$200,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AtriCure Inc is $51.50, about 29.2% above its October 28 closing price of $36.45

Press Release: ID:nBw74J3VTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)